Shares of Pyxis Oncology (PYXS) slid 8.6% to $2.65 in early trading Tuesday after the clinical-stage biotech priced a public offering of shares and warrants expected to raise roughly $110 million — a move that floods the market with new stock and gives existing shareholders a smaller slice of the pie. Pyxis Oncology Floods the Market With New Shares to Fund Its Cancer Drug — Will the Bet Pay Off Before the Cash Runs Out?
Shares of Pyxis Oncology (PYXS) dropped 8.6% to $2.65 Tuesday morning after the clinical-stage biotech priced a massive dilutive offering — a fundraising move that raises the stakes on a cancer drug still years from generating meaningful revenue.
The Offering Nearly Doubles the Share Count — and That's Before the Warrants
The deal involves 36.05 million shares of common stock and pre-funded warrants for another 1.88 million shares, priced at $2.90 per unit. With roughly 64 million weighted average shares outstanding as of the latest quarter , the new issuance alone expands the share base by nearly 60%. But the real overhang is bigger: the deal includes warrants to buy up to 49.31 million additional shares at $3.50, which could raise another $172.6 million if exercised. That means the total potential dilution — meaning more shares splitting ownership of the same company — could exceed 87 million shares.
The Company Was Running Out of Money This offering was not a luxury. As of March 31, Pyxis had just $42.5 million in cash with runway projected only into Q4 2026.
A private placement earlier this year extended that to the second quarter of 2027 , but the company posted trailing 12-month net losses of roughly $79.6 million — burning cash at a pace that demanded fresh capital. The $110 million in gross proceeds buys time, but on terms that punish existing shareholders.
The Drug Data Is Encouraging — But the Finish Line Is Distant
Updated Phase 1 results, disclosed September 9, showed MICVO — Pyxis's lead cancer drug targeting hard-to-treat head and neck tumors — achieved a 36% response rate and 94% disease control rate among 33 evaluable patients. Those numbers look promising. The data support advancing into a pivotal Phase 3 trial planned for mid-2027 , with overall survival readouts expected in the first half of 2027. But Phase 3 trials are enormously expensive and multi-year affairs; this $110 million may not be the last time Pyxis passes the hat.
Warrant Structure Adds a Twist
The new warrants cannot be exercised until shareholders vote to authorize more shares — a step that introduces uncertainty and makes the timeline for full dilution unclear. For investors, the stock's near-term ceiling is effectively capped by the $3.50 warrant exercise price, while the floor remains vulnerable to the cash-burn math of an unprofitable biotech with no approved product. The clinical promise is real; so is the price of funding it.